Akèy › Kansè vejik › Texas

Etid klinik pou Kansè vejik nan Texas

51 etid pou Kansè vejik ap chèche patisipan nan sit nan Texas.

Vil nan Texas

Tèks ofisyèl etid la (Anglè)

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

The University of Texas MD Anderson Cancer Center - Conroe, Conroe
University of Texas MD Anderson Cancer Center, Houston
The University of Texas, MD Anderson Cancer Center - West Houston, Houston
ak 3 plis

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07090499

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Parkland Memorial Hospital, Dallas
UT Southwestern Simmons Cancer Center - RedBird, Dallas
UT Southwestern/Simmons Cancer Center-Dallas, Dallas
ak 5 plis

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07061964

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

The University of Texas MD Anderson Cancer Center, Houston

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06172478

A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

Texas Oncology-Austin Central ( Site 0107), Austin
Urology Austin, PLLC ( Site 0109), Austin

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06833073

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

UT Southwestern Simmons Cancer Center - RedBird, Dallas
UT Southwestern/Simmons Cancer Center-Dallas, Dallas
UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
ak 1 plis

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT03866382

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

Texas Oncology, Austin
Texas Oncology - Northeast Texas, Tyler

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07566156

Enfortumab Vedotin and Stereotactic Radiation for Localized Bladder Cancer

UT Southwestern Medical Center, Dallas

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06394570

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

Texas Oncology - Central/South Texas, Austin
Texas Oncology - Central/South Texas, Austin
Texas Oncology - Central/South Texas, Austin
ak 13 plis

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07421700

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

START Dallas Fort Worth, Fort Worth
MD Anderson, Houston
NEXT Oncology Houston, Houston
ak 1 plis

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07277413

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

Cancer Center Outpatient Building, Dallas
The University of Texas Southwestern Medical Center, Dallas
UT Southwestern Medical Center - West Campus Building, Dallas
ak 5 plis

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07206225

DESTINY-PANTUMOUR04

Research Site, Dallas

Ap rekriteEtid obsèvasyon

Laj 18 a 130 · Tout sèks · Mizajou Sep 25, 2026 · NCT07124000

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

USO-Texas Oncology-Central/South Texas, Austin
World Research Link, Baytown
Parkland Health and Hospital System, Dallas
ak 5 plis

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07218380

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Texas Oncology (Balcones) - SCRI, Austin
MD Anderson Cancer Center, Houston
START South Texas Accelerated Research Therapeutics, San Antonio

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT05267626

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

MD Anderson Cancer Center, Houston

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT07217171

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

UT Southwestern Medical Center, Dallas
DHR Health Advance Care Center, Edinburg
The Center for Cancer and Blood Disorders, Forth Worth
ak 1 plis

Ap rekriteEtid obsèvasyon

Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT05059444

A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)

Urology Austin, PLLC ( Site 0008), Austin

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT07222488

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

University of Texas MD Anderson Cancer Center, Houston
South Texas Accelerated Research Therapeutics (START), San Antonio

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT06465069

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06760819

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

UPNT Research Institute, LLC, Arlington
Urology Austin, PLLC (Urology America), Austin
Urology Clinics of North Texas, PLLC, Dallas
ak 3 plis

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06567743

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

The Don and Sybil Harrington Cancer Center, Amarillo
UT MD Anderson Cancer Center, Houston
Audie L Murphy VA Hospital, San Antonio

Ap rekriteEtid obsèvasyonVolontè an sante akeyi

Laj 40 a 75 · Tout sèks · Mizajou Sep 2, 2026 · NCT05334069

Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)

University of Texas Southwestern Medical Center, Dallas
University of Texas Health Science Center at San Antonio, San Antonio

Ap rekriteEtid obsèvasyon

Laj 18 a 99 · Tout sèks · Mizajou Aug 24, 2026 · NCT05825950

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

Urology Partners of North Texas, Arlington
Urology Austin, LLC, Austin
Houston Metro Urology, Houston
ak 2 plis

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Aug 24, 2026 · NCT05951179

Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer

Urology Partners of North Texas, Arlington
Houston Metro Urology, Houston

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Aug 21, 2026 · NCT07480356

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

University of Texas Southwestern, Dallas
Texas Oncology, P.A, Dallas
MD Anderson Cancer Center, Houston

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT05614739

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Research Site, Dallas

Ap rekriteFaz 2/3

Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT07129993

Measuring Surgical Recovery After Radical Cystectomy

University of Texas - Southwestern, Dallas
University of Texas MD Anderson Cancer Center, Houston

Ap rekriteEtid obsèvasyon

Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT03193970

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

MD Anderson in The Woodlands, Conroe
Parkland Memorial Hospital, Dallas
UT Southwestern/Simmons Cancer Center-Dallas, Dallas
ak 4 plis

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT07097142

A Study of MGC026 in Participants With Advanced Solid Tumors

The University of Texas MD Anderson Cancer Center, Houston
University of Texas Health Science Center at Houston, Houston

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT06242470

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

The University of Texas, MD Anderson Cancer Center, Houston
UT Health Mays Cancer Center, San Antonio

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT05592626

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Urology Austin, Austin
UT Southwestern Medical Center, Dallas
Houston Metro Urology, Houston
ak 2 plis

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Aug 7, 2026 · NCT04752722

IDOV-Immune for Advanced Solid Tumors

MD Anderson Cancer Center, Houston
South Texas Accelerated Research Therapeutics, San Antonio

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT06910657

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

Texas Oncology - West Texas, Abilene
Local Institution - 0187, Austin

Ap rekriteFaz 2/3

Laj 18 ak plis · Tout sèks · Mizajou Jul 29, 2026 · NCT07106762

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Baylor Scott & White Research Institute, Dallas
University of Texas MD Anderson Cancer Center, Houston
Baylor Scott & White Medical Center, Temple

Ap rekriteFaz 2

Laj 8 ak plis · Tout sèks · Mizajou Jul 27, 2026 · NCT05503797

An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

Research Site, Dallas

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Jul 22, 2026 · NCT07720284

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Baylor Scott and White Research Institute, Dallas
The University of Texas MD Anderson Cancer Center, Houston
Baylor Scott & White Medical Center - Temple, Temple

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Jul 22, 2026 · NCT04879329

A First in Human Study of PLT012 in Participants With Solid Tumor Cancers

NEXT Dallas, Dallas
MD Anderson Cancer Center, Houston
NEXT Houston, Houston

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Jul 7, 2026 · NCT07337525

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Oncology Consultants, PA, Houston
Oncology Consultants, PA., Houston
The University of Texas M.D. Anderson Cancer Center, Houston
ak 5 plis

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Jul 6, 2026 · NCT04389632

Predicting BCG Response

University of Texas Southwestern, Dallas

Ap rekriteEtid obsèvasyon

Laj 18 a 90 · Tout sèks · Mizajou Jul 6, 2026 · NCT04564781

Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.

Austin Urology Institute, Austin
UT Southwestern Medical Center, Dallas

Ap rekrite

Laj 18 a 88 · Tout sèks · Mizajou Jul 2, 2026 · NCT06394869

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)

JPS Health Network, Forth Worth
Baylor Scott and White Biorepository, Temple

Ap rekriteEtid obsèvasyon

Laj 18 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT07327489

Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.